Shares of Kura Oncology, Inc. (NASDAQ:KURA) have earned an average recommendation of “Buy” from the seven research firms that are presently covering the firm, Marketbeat reports. Two analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $17.67.
Several research firms have commented on KURA. ValuEngine cut shares of Kura Oncology from a “hold” rating to a “sell” rating in a research report on Friday, September 1st. Zacks Investment Research cut shares of Kura Oncology from a “buy” rating to a “hold” rating in a report on Wednesday, September 6th. Cann reaffirmed a “buy” rating on shares of Kura Oncology in a report on Wednesday, November 8th. Leerink Swann reaffirmed an “outperform” rating and issued a $18.00 price target (up previously from $16.00) on shares of Kura Oncology in a report on Thursday, August 10th. Finally, Cowen and Company started coverage on shares of Kura Oncology in a report on Thursday, September 7th. They issued an “outperform” rating on the stock.
Kura Oncology (NASDAQ:KURA) opened at $15.10 on Wednesday. Kura Oncology has a 1 year low of $4.72 and a 1 year high of $16.75. The company has a debt-to-equity ratio of 0.07, a quick ratio of 13.48 and a current ratio of 13.48.
Kura Oncology (NASDAQ:KURA) last posted its earnings results on Tuesday, November 7th. The company reported ($0.38) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.37) by ($0.01). research analysts expect that Kura Oncology will post -1.45 earnings per share for the current year.
ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by Markets Daily and is owned by of Markets Daily. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of United States & international trademark & copyright law. The legal version of this piece of content can be accessed at https://www.themarketsdaily.com/2017/11/15/kura-oncology-inc-kura-receives-consensus-recommendation-of-buy-from-analysts.html.
Several large investors have recently bought and sold shares of the stock. Candriam Luxembourg S.C.A. bought a new stake in shares of Kura Oncology in the 3rd quarter worth approximately $8,073,000. Vanguard Group Inc. grew its stake in Kura Oncology by 13.0% in the 2nd quarter. Vanguard Group Inc. now owns 433,868 shares of the company’s stock valued at $4,035,000 after buying an additional 50,033 shares in the last quarter. Morgan Stanley grew its stake in Kura Oncology by 175.5% in the 1st quarter. Morgan Stanley now owns 430,428 shares of the company’s stock valued at $3,788,000 after buying an additional 274,166 shares in the last quarter. Alethea Capital Management LLC grew its stake in Kura Oncology by 128.1% in the 2nd quarter. Alethea Capital Management LLC now owns 193,346 shares of the company’s stock valued at $1,798,000 after buying an additional 108,577 shares in the last quarter. Finally, EAM Investors LLC purchased a new position in Kura Oncology in the 3rd quarter valued at approximately $2,884,000. 39.11% of the stock is currently owned by institutional investors.
Kura Oncology Company Profile
Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.
Receive News & Ratings for Kura Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.